comparemela.com

Latest Breaking News On - Innova captab gmp - Page 1 : comparemela.com

Innova Captab grey market premium at 7% ahead of stock market listing today

The Innova Captab IPO, which ran from December 21 and December 26, received a strong investor response, receiving bids of 50,16,58,245 shares against the offered 90,78,010 equity shares. In total, the issue was subscribed 55.26 times. 

Himachal-pradesh
India
Ministry-of-science
Innova-captab-ltd
Industrial-research
Laurus-labs-ltd
Department-of-scientific
Torrent-pharma
Innova-captab
Innova-captabsold
Innova-captab-listing

Innova Captab IPO shares to list on Friday; grey market premium nosedives

Will Innova Captab see double-digit gains on debut?

Innova Captab is set to debut on the bourses on December 29. This is going to be the last mainboard listing for the current calendar year

Himachal
Uttaranchal
India
Prathamesh-masdekar
Manoj-kumar-lohariwala
Saral-seth
Ajanta-pharma
Sharon-bio
Intas-pharmaceuticals
Emcure-pharmaceuticals
Cipla
Glenmark-pharmaceuticals

Innova Captab IPO allotment – How to check allotment, GMP, listing date and more

Innova Captab is expected to announce its share allotment status on Wednesday, December 27.The shares of Innova Captab were subscribed 55.24 times.The shares

Click-on-company-selection
Innova-captab
Company-selection
Innova-captab
Innova-captab-listing
Innova-captab-ipo-gmp
Innova-captab-ipo-allotment
Innova-captab-ipo
Innova-captab-gmp
Innova-captab-allotment

Innova Captab IPO Day 3: Check latest subscription details and grey market premium on final day of bidding

Innova Captab has seen a strong surge in subscriptions on the final day even as its grey market premium has witnessed a decline. Here are all the key details about the IPO such as the latest subscription numbers, grey market premium and more.

Koustav-das
Innova-captab
Kfin-technologies
Innova-captab-details
Innova-captab-ipo-details
Innova-captab-listing
Innova-captab-gmp
Nnova-captab-subscription-details-

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.